Application of tadalafil in preparation of medicine for treating tricuspid valve insufficiency
By mixing tadalafil with lactose and other excipients, it is prepared into tablets for the treatment of tricuspid valve incomplete closure, the problems of unsatisfactory treatment and high risk of surgery in the prior art are solved, and direct drug treatment without surgery is achieved , significantly alleviate the symptoms of tricuspid valve insufficiency.
Patent Information
- Application Number
- CN202411227628.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The drugs for treating tricuspid valve insufficiency in the prior art are not ideal, and the clinical surgical treatment is expensive and has high risk.
Tadalafil is used as the main drug, and tadalafil is prepared into tablets by mixing it with lactose, croscarmellose sodium, hydroxypropyl cellulose and other auxiliary materials. The dose is 0.5-40 mg/day, the therapeutic drugs were prepared by wet granulation and tableting process.
Drug treatment is directly performed without surgery. Take one tablet a day to treat symptoms of tricuspid valve insufficiency such as atrial fibrillation, palpitations, and limb swelling. It completely disappears after continuous use, significantly improving the treatment effect.
Smart Images

Figure CN118924757A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and more specifically to the use of tadalafil in preparing a medicine for treating tricuspid valve insufficiency. Background Art
[0002] Tricuspid regurgitation is mostly caused by pulmonary hypertension and tricuspid valve dilatation. It is common in significant mitral valve disease and chronic cor pulmonale, myocardial infarction involving the inferior wall of the right ventricle, late stage of heart failure caused by pulmonary hypertension due to rheumatic or congenital heart disease, ischemic heart disease, cardiomyopathy; rare cases include shortening and deformation of the valve after rheumatic tricuspid valvulitis, often combined with tricuspid stenosis; congenital Ebstein malformation; valve damage caused by infective endocarditis; tricuspid valve prolapse, such patients are often accompanied by mitral valve prolapse, common in Marfan syndrome; can also be seen in right atrial myxoma, right ventricular myocardial infarction and after chest trauma.
[0003] The pathophysiological changes caused by tricuspid regurgitation on the right side of the heart are similar to the effects of mitral regurgitation on the left side of the heart, but the compensatory period is longer; if the disease progresses gradually, it can eventually lead to hypertrophy of the right ventricle and right atrium, and right ventricular failure. If it is caused by significant pulmonary hypertension, the disease progresses faster.
[0004] Patients may first have a long symptom-free period, and then gradually develop clinical symptoms such as palpitations, chest tightness, and dizziness. If the symptoms worsen further, it may lead to heart failure or even sudden death.
[0005] 1. Symptoms: When tricuspid regurgitation is combined with pulmonary hypertension, symptoms of decreased cardiac output and systemic congestion may occur. For patients with tricuspid regurgitation combined with mitral valve disease, the symptoms of pulmonary congestion may be alleviated due to the development of tricuspid regurgitation, but fatigue and other symptoms of decreased cardiac output may be aggravated. Atrial fibrillation, palpitations, and limb weakness are the main clinical manifestations of this disease.
[0006] 2. Signs: The main sign is a full systolic murmur at the lower left edge of the sternum. The murmur may be enhanced after inspiration and compression of the liver; however, if the failing right ventricle cannot increase the stroke volume, the murmur is difficult to enhance. Only when the flow is large, there is a third heart sound and a low-pitched mid-diastolic murmur in the tricuspid valve area. The jugular venous pulse waveform V wave (called the regurgitation wave, caused by the blood returning to the right atrium vein when the right ventricle contracts) is enlarged again; the liver pulsation can be palpated. In case of valve prolapse, a non-jet click sound can be heard in the tricuspid valve area. Its congestion signs are the same as those of right heart failure. Some patients may experience lower limb edema. Due to insufficient blood supply, nutrients cannot be transmitted to the whole body, especially below the ankles, and malnutrition leads to lower limb edema.
[0007] At present, the methods for treating tricuspid regurgitation mainly include drug treatment and surgical treatment. Among them, drug treatment mainly uses diuretics hydrochlorothiazide and spironolactone; digitalis drugs digitalis and digoxin; vasodilators nitroglycerin and isosorbide dinitrate; the effect of drugs for treating tricuspid regurgitation in the existing technology is not ideal. Therefore, it is necessary to strengthen the research on the treatment of tricuspid regurgitation to improve the treatment effect of tricuspid regurgitation. For clinical surgical treatment methods, patients not only need to pay high costs, but also have high risks, which causes great pain to patients.
[0008] Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase 5 (PDE5). When sexual stimulation leads to the local release of nitric oxide, PDE5 is inhibited by tadalafil, which increases the level of cGMP in the corpus cavernosum of the penis, which leads to smooth muscle relaxation, blood flow into the penile tissue, and erection, as in the absence of sexual stimulation. The current clinical indications of tadalafil tablets are mainly for the treatment of erectile dysfunction and pulmonary hypertension. At present, there are no reports on the use of tadalafil in the treatment of tricuspid valve regurgitation. Summary of the invention
[0009] The purpose of the present invention is to solve the technical problems that the drugs used to treat tricuspid regurgitation in the prior art are not effective and the clinical surgical treatment methods are expensive and risky.
[0010] In order to solve the above technical problems, the present invention provides the use of tadalafil in preparing a drug for treating tricuspid regurgitation, wherein the dosage of the drug for treating tricuspid regurgitation is 0.5-40 mg / day.
[0011] Preferably, the drug for treating tricuspid regurgitation comprises a pharmaceutically acceptable excipient.
[0012] Preferably, the pharmaceutical dosage form for treating tricuspid regurgitation comprises a tablet.
[0013] Preferably, the method for preparing the drug comprises the following steps:
[0014] (1) Remove the outer packaging of the purchased tadalafil, accurately weigh 1000 g, ultrafinely grind the tadalafil particles into powder with a diameter of 100-500 nm, then add 17.88 kg of lactose thereto, mix well, then add 900 g of croscarmellose sodium and 70 g of sodium lauryl sulfate, and mix well to obtain a powder referred to as T mixed powder;
[0015] (2) Preparation of hydroxypropyl cellulose solution: accurately weigh 575 g of hydroxypropyl cellulose, then add 6.612 kg of deionized water thereto, and stir until clear and transparent to prepare a hydroxypropyl cellulose solution;
[0016] (3) Add the T mixed powder prepared in step (1) to the hydroxypropyl cellulose solution, wet granulate, dry and granulate, then add 3.75 kg of microcrystalline cellulose, 700 g of cross-linked carboxymethyl cellulose sodium and 125 g of magnesium stearate, mix well, compress and coat the tablets, and package them in PVC to obtain a drug for treating tricuspid regurgitation.
[0017] Preferably, the dosage of the drug for treating tricuspid regurgitation is 2.5 mg / day.
[0018] Preferably, the drug for treating tricuspid regurgitation can reduce the symptoms of atrial fibrillation, palpitations, and limb edema to normal levels when treating tricuspid regurgitation.
[0019] Compared with the prior art, the beneficial effects of the present invention are as follows: the present invention provides the use of tadalafil in the preparation of a drug for treating tricuspid regurgitation. Compared with the prior art, no surgery is required and drug treatment can be directly performed; one tablet of the drug is taken a day; the therapeutic effect of treating tricuspid regurgitation is significant, which is mainly reflected in: the symptoms of tricuspid regurgitation, such as atrial fibrillation, lower limb edema and the like, completely disappear after continuous use for a period of time, and the main clinical manifestations are: atrial fibrillation, palpitations, limb edema and the like are effectively relieved. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is a process flow chart for preparing a drug for treating tricuspid regurgitation in an embodiment of the present invention;
[0021] Figure 2 1 is a diagram showing the therapeutic effects of different drugs on hypertension caused by traumatic tricuspid regurgitation in dogs in an embodiment of the present invention; in the figure, 1 represents the negative control group, 2 represents the positive control group, 3 represents the tadalafil group, 4 represents the sham operation group, the horizontal axis represents the number of days of drug treatment, and the vertical axis represents the pulmonary dynamic pressure (mmHg). DETAILED DESCRIPTION
[0022] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in combination with the accompanying drawings and embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0023] The test materials and reagents used in the following examples, unless otherwise specified, can be obtained from commercial sources. The tadalafil raw materials in the examples were purchased from Lunan Pharmaceutical Group. If no specific technology or conditions are specified, they can be carried out according to the technology or conditions described in the literature in this field or according to the product instructions.
[0024] Example 1: Establishment of a canine traumatic tricuspid regurgitation animal model
[0025] 1. Experimental animals and grouping: 15 male beagles, aged (15±2) months and weighing (15±0.5) kg, were randomly divided into 4 groups. Among them: 3 negative control groups (normal saline); 3 positive control groups (desinophils); 6 treatment groups (tadalafil tablets); 3 sham operation groups (normal saline). Traumatic tricuspid regurgitation was modeled by surgical trauma, and the ratio of tricuspid regurgitation area to right atrium area was between 40% and 70%.
[0026] 2. Animal preparation: After the dog is weighed, ketamine injection (5mg / kg) and diazepam injection (1mg / kg) are injected intramuscularly for basic anesthesia. Intravenous access is established, and the dog is intubated and ventilated. The dog is placed in the left lateral position, the right chest and limbs are skinned, and electrodes are attached to the limbs for ECG monitoring. Cefuroxime (0.75g / dog) is injected intravenously 0.5 hours before the operation to prevent infection. Ari, fentanyl and propofol injections are used to maintain anesthesia during the operation.
[0027] 3. Establishing animal model:
[0028] 1. Make an incision on the right chest, enter the chest through the fourth intercostal space, and expose the pericardium. Cut and suspend the pericardium about 1.5 cm in front of the right phrenic nerve to expose the right atrium and the superior and inferior veins. Pass No. 7 silk thread through the superior and inferior vena cava, and use the rubber tube to cover the thread for later use.
[0029] 2. Two 5-0 Prolene lines were placed in advance at the site of the planned incision on the right atrium free wall for lifting and blocking the upper and lower cavities. The right atrium was quickly cut open during surgery to expose the tricuspid valve. Beagles were randomly selected to only cut off the anterior leaflet of the tricuspid valve and its attached chordae. After completing the intracardiac operation, the superior and inferior vena cava blocking lines were loosened, the air was exhausted, the pre-placed sutures of the right atrium incision were quickly aligned, and the incision was clamped with an atrial appendage clamp, and the incision was sutured continuously with 5-0 Prolene.
[0030] 3. After the right atrium was opened in the sham operation group, no intracardiac operation was performed. When the superior and inferior vena cava blocking time was close to that of the operation group, about 90 seconds later, the blocking line was released, and the rest of the operations were the same as those of the operation group.
[0031] 4. Observation indicators:
[0032] During the feeding period, the dogs' appetite, activity, and abdominal and limb edema were observed. At 3 and 4 months, the dogs were weighed, anesthetized with the same anesthesia scheme, and chest echocardiograms were performed. The main test indicators were as follows: pulmonary hypertension, atrial fibrillation, limb edema, etc.
[0033] 5. Statistical methods
[0034] SPSS 19.0 statistical software was used for analysis. Group analysis was adopted. The measurement data were expressed as mean ± standard deviation. Repeated measures analysis of variance was used for inter-group analysis.
[0035] Example 2: Treatment of tricuspid valve insufficiency with tadalafil tablets
[0036] After the canine traumatic tricuspid regurgitation model was established, the dogs were kept for 3 months after surgery, during which time the pulmonary artery blood pressure, atrial fibrillation, limb edema and other indicators of the dogs were detected. 3 months after surgery, the above indicators of the dogs showed the above symptoms caused by tricuspid regurgitation ( Figure 1 ; Table 1). Starting from the 4th month, the present invention uses tadalafil tablets to treat tricuspid regurgitation for 28 consecutive days, 1 tablet per day, 2.5 mg per tablet (the optimal dose was 2.5 mg from 0.1 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, and 20 mg in the preliminary experiment). From the experimental results ( Figure 1 ; Table 1):
[0037] Dogs with traumatic tricuspid regurgitation were treated with tadalafil tablets for 28 consecutive days. The pulmonary artery blood pressure was reduced to normal on the fourth day of medication, while the positive control digoxin needed 16 days to lower the pulmonary artery blood pressure. This was mainly because digoxin had a poor effect on pulmonary artery blood pressure caused by tricuspid regurgitation. The dogs lost weight significantly, and digoxin caused poisoning in the dogs, resulting in insignificant efficacy of digoxin.
[0038] A dog with traumatic tricuspid regurgitation was treated with tadalafil tablets for 28 consecutive days, and the dog's weight began to increase, indicating that tadalafil tablets have little toxicity and side effects, good efficacy, and can effectively treat the symptoms caused by tricuspid regurgitation.
[0039] A dog with traumatic tricuspid regurgitation was treated with tadalafil tablets for 28 consecutive days. The dog's atrial fibrillation, lower limb edema, and other symptoms were effectively treated, and basically returned to normal levels after 28 days. It can be inferred that tadalafil tablets are significantly effective in treating tricuspid regurgitation.
[0040] Table 1 The therapeutic effect of tadalafil tablets on traumatic tricuspid regurgitation in dogs
[0041]
[0042] The embodiments of the present invention disclose preferred embodiments, but are not limited thereto. A person skilled in the art can easily understand the spirit of the present invention based on the above embodiments and make different extensions and changes. However, as long as they do not deviate from the spirit of the present invention, they are all within the protection scope of the present invention.
Claims
1. Use of tadalafil in the preparation of a medicament for treating tricuspid regurgitation, characterized in that: The dosage of the drug for treating tricuspid regurgitation is 0.5-40 mg / day.
2. The use according to claim 1, characterized in that: The drug for treating tricuspid regurgitation comprises pharmaceutically acceptable excipients.
3. The use according to claim 2, characterized in that: The pharmaceutical dosage form for treating tricuspid regurgitation includes tablets.
4. The use according to claim 3, characterized in that: The preparation method of the drug comprises the following steps: (1) Remove the outer packaging of the purchased tadalafil, accurately weigh 1000 g, ultrafinely grind the tadalafil particles into powder with a diameter of 100-500 nm, then add 17.88 kg of lactose thereto, mix well, then add 900 g of croscarmellose sodium and 70 g of sodium lauryl sulfate, and mix well to obtain a powder referred to as T mixed powder; (2) Preparation of hydroxypropyl cellulose solution: accurately weigh 575 g of hydroxypropyl cellulose, then add 6.612 kg of deionized water thereto, and stir until clear and transparent to prepare a hydroxypropyl cellulose solution; (3) Add the T mixed powder prepared in step (1) to the hydroxypropyl cellulose solution, wet granulate, dry and granulate, then add 3.75 kg of microcrystalline cellulose, 700 g of cross-linked carboxymethyl cellulose sodium and 125 g of magnesium stearate, mix well, compress and coat the tablets, and package them in PVC to obtain a drug for treating tricuspid regurgitation.
5. The use according to claim 4, characterized in that: The dosage of the drug for treating tricuspid regurgitation is 2.5 mg / day.
6. The use according to any one of claims 1 to 5, characterized in that: The drug for treating tricuspid regurgitation can make the symptoms of atrial fibrillation, palpitation and limb edema reach normal levels when treating tricuspid regurgitation.
Citation Information
Cited By
New application of tadalafil in treatment of recurrent abortion
CN117797153A
